References
- AHMED, A. C., and TRIEFF, N. M., 1983, Aliphatic nitriles; metabolism and toxicity. In Progress in Drug Metabolism, Vol. 7, edited by J. M. Bridges and L. F. Chasseaud (London: John Wiley), pp. 229–294.
- BERGSTRAND, R., VEDIN, A., WILHELMSSON, C., PETERSON, L.-E., CHAMBERLAIN, J., DELI., D., STEVENS, L. A., and OSTROWSKI, J., 1984, Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study. European Journal of Clinical Pharmacology, 27, 203–208.
- BOEHME, E., SPIES, C., and GROSSMAN, G., 1982 a, Wirksamer metabolit von molsidomin und stimulation der cymt-bildung durch sydnonimine. In Molsidomin, Neue Aspekte zur Therapie der ischamischen Herzerkrankung, 3. Internationales Symposium, Rottach-Ergen 1982, edited by E. Bassenge and H. Sclunutzler (Muchen-Wien and Baltimore: Urban and Schwarzenberg), pp. 37–46.
- BOEHME, E., GROSSMAN, G., and SPIES, C., 198213, Active metabolites of molsidomin and other sydnonimine derivatives. Naunyn-Schmiedeberg's Archives of Pharmacology, 321, (Suppl.), 164.
- CHATFIELD, D. H., 1976, Disposition and metabolism of some nitrofurylthiazoles possessing antiparasitic activity. Xenobiotica, 6, 509–520.
- DELL, D., and CHAMBERLAIN, J., 1978, Determination of molsidomine in plasma by high performance liquid chromatography. Journal of Chromatography, 146, 465–472.
- FROMSON, J. M., ILLING, H. P. A., Nos, R. M. J., JOHNSON, K. I., JOHNSON, P., OsmowsKi, J., SCHRAVEN, E., and STEWARD, A., 1981, Absorption and disposition of ['4C1-molsidomine in laboratory animals. Arzneimittel-Forschung, 31, 337–345.
- GIBALDI, M., and PERRIER, D., 1982, Pharmacokinetics, 2nd edition (New York: Marcel Dekker), p. 336.
- HAYASH T., 1982, Metabolism of 4-ethoxy -2-methy1-5-morpholi no- 3(2 H)- p y ridazinone (Emorfazone).V.1) Effect of inducer pretreatment on oxygenation of the morpholino moiety in guinea pigs. Chemical and Pharmaceutical Bulletin, 30, 3748–3756.
- INGS, R. M. J., PIIKIEN, A. W., and JOHNSON, D., 1980, In World Conference on Clinical Pharmacology and Therapeutics, Abstract 0416, edited by P. Turner and C. Padgham (London: Macmillan).
- JOHNSON, P., RISING, P. A., and RISING, T. J., 1972, Liquid scintillation counting of biological samples using external standardization and automatic data processing. In Liquid Scintillation Counting, edited by M. A. Crook, I'. Johnson and B. Scales (London: Heyden), pp. 267–277.
- KANAMORI, M., NISHIKAWA, M., ENDO, T., FUJIWARA, M., and HIDAKA, H., 1981, Effect of molsidomine and its metabolites on human platelet aggregation and guanylate cyclase activity. Japanese Journal of Pharmacology, 31, (Suppl.), 148.
- MASUDA, K., TONGA, T., and HAYASHI, N., 1975, Synthesis of 3-morpholino-N-ethoxy-carbonylsydnonimine-5-"C (Sin-10-'4C). Journal of Labelled Compounds, 11, 301–304.
- NISHIKAWA, M., KANAMORI, M., and HIDAKA, H., 1982, Inhibition of platelet aggregation and stimulation of guanylate cyclase activity by an antianginal agent molsidomine and its metabolites. Journal of Pharmacology and Experimental Therapeutics, 220, 183–190.
- ROWLAND, M., and Tozru, 'T'., 1980, Clinical Pharmacokinetics : Concepts and Applications (Philadelphia: Lea and Febiger), p. 197.
- SUMIDA, S., 1974, Study on the effects of moldisomine, its metabolite, 3-morpholinosydnonimine-hydrochloride and carbocromen on platelet aggregation and thrombus formation. Japanese Journal of Clinical and Experimental Medicine, 51, 243–247.
- TANAYAMA, S., NAKAI, Y., FUJITA, T., SUZUOKI, Z., IMASHITO, Y., and MASUDA, K., 1974, Biotransform-ation of molsidomine (N-ethoxycarbony1-3-morpholino-sydnonimine), a new antianginal agent in rats. Xenobiotica, 4, 175–191.
- WILSON, I. D., WATSON, K. V., TROKE, J., 11.1.ING, II. P. A., FROMSON, J. M., and SCHRAVEN, E., 1986, The metabolism tit' tisqN-ethoxycarbony1-3-morpholinosydnonimine (molsidomine) in labora-tor ammal.s. Xenobiotica, 16, 1117 1128.
- YAMAKADO T. NISHIKAWA, M., and I IIDAKA, II., 1982, Stimulation of human platelet guanylate cyclaseby nitroso compounds, Thrombosis Research, 26, 135–140.